ICU MEDICAL INC/DE(ICUI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ICU MEDICAL INC/DE (ICUI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICUI at 49.0/100 on a 32-signal composite quality model, placing it at rank #1,687 of 2,962 stocks — the bottom half of the AI-ranked universe. ICUI scores in the top quartile across earnings quality (97.4). Areas of concern include revenue growth (17.9) and balance sheet strength (39.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ICU MEDICAL INC/DE reports quarterly revenue of $551.7M, net income of $19.1M, an operating margin of 7.1%. Top institutional holders of ICUI by reported 13-F value include BlackRock, Jupiter Topco, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ICUI trades on the Nasdaq exchange and files with the SEC under CIK 883984. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICUI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ICU MEDICAL INC/DE directly from SEC EDGAR.